ANDOVER, Mass., Jan. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 12, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares of its common stock and an aggregate of 15,817 restricted stock units to 16 employees, each as a material inducement for each employee's entry ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2023 was $66.4 million, representing a 159% increase year-over-year and a 27% sequential increase from Q2 2023 [17][61] - U.S. transplant revenue was $59.7 million, a 156% increase from Q3 2022, including $2.1 million from logistics revenue [39][62] - Gross margin for Q3 2023 was 61%, lower than Q2 2023 due to integration inefficiencies and legacy operations [25][40] - Net loss for Q3 2023 was $25.4 million, compared to $7.4 million in Q3 2022 [42] Business Line Data and Key Metrics Changes - Transplant-related activities accounted for $64 million of total revenue, with $2.1 million from NOP aviation and logistics [17][62] - NOP contributed 97% of total U.S. cases in Q3, with 98% of liver, 93% of heart, and 97% of lung cases from NOP [33] - The company added 45 new clinical specialists and 10 surgeons in Q3 to meet growing demand [19] Market Data and Key Metrics Changes - The company continues to dominate DCD heart donations in the U.S., capturing over 70% of the market [3][5] - U.S. revenue breakdown included $41.2 million from liver, $15.1 million from heart, and $3.4 million from lung [39] Company Strategy and Development Direction - The company aims to reach 10,000 NOP transplants annually by 2028, leveraging new technologies from recent acquisitions [36][68] - A new logistics digital command and dispatch center is being built to enhance operational efficiency, expected to be operational by Q1 2024 [35] - The company plans to exit the legacy charter business by early 2024, with minimal revenue expected in Q4 [24][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the NOP model and the positive impact of logistics on revenue [31][35] - The company is cautious about Q4 guidance due to ongoing operational challenges and staffing needs [70] - Management highlighted the economic benefits of NOP for payers, emphasizing the importance of outcomes and quality of care [90] Other Important Information - The company has acquired eight planes for its transplant logistics fleet, with plans to expand to 15-20 operational planes by mid-2024 [58] - The company expects gross margins to improve over the next few quarters as operational efficiencies are realized [59][66] Q&A Session Summary Question: What is leading to caution in Q4 guidance? - Management indicated that staffing is not fully complete and operational challenges remain, despite encouraging trends in October [70] Question: What are the growth aspirations for 2024? - Management noted that while they are not issuing guidance for 2024 yet, they expect significant growth based on current momentum [72] Question: Can you provide metrics around the aviation business? - Management stated it is too early to provide detailed metrics, focusing instead on revenue growth and service margin improvement [75] Question: What is the average revenue per case for aviation? - Management indicated that average revenue varies significantly based on distance, ranging from $25,000 to $100,000 [77] Question: How is the clinical staff expansion progressing? - Management confirmed that the impact of new hires will be seen in Q4, with ongoing investments to support growth into 2024 [84]

TransMedics Group, Inc. (NASDAQ:TMDX) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon - CFO Conference Call Participants Bill Plovanic - Canaccord Allen Gong - JPMorgan Suraj Kalia - Oppenheimer Ryan Daniels - William Blair Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol( ...

Transmedics Group, Inc. (NASDAQ:TMDX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - Founder, President, CEO & Director Stephen Gordon - CFO, Treasurer & Secretary Conference Call Participants William Plovanic - Canaccord Genuity Allen Gong - JPMorgan Chase & Co. Cecilia Furlong - Morgan Stanley Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome to TransMedics First Quarter 2023 Earnings Conference Call. [Operator ...

Transforming Organ Transplantation Therapy Worldwide Projections, estimates, industry data and information contained in this presentation, including the Company's general expectations and market position and market opportunity, are based on information from thirdparty sources and management estimates. Although the Company believes that its third-party sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources. The Company's management estimates are derived from third-part ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 83-2181531 (State or other jurisd ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ET Company Participants Brian Johnston – Gilmartin Group Waleed Hassanein – President and Chief Executive Officer Stephen Gordon – Chief Financial Officer Conference Call Participants Cecilia Furlong – Morgan Stanley Josh Jennings – Cowen Bill Plovanic – Canaccord Suraj Kalia – Oppenheimer Operator Good afternoon, and welcome to the TransMedics Fourth Quarter and Full Year 2022 Earnings Conference Call. All part ...